Catherine Coombs, MD, discusses Bruton’s tyrosine kinase inhibitors at the 2022 SOHO Annual Meeting. As treatments for CLL evolve, new challenges have arisen to address the disease’s resistance to targeted therapies. Because WM is considered incurable, an important treatment consideration is optimization of quality of life. Zanubrutinib led to significant PFS improvements compared with bendamustine plus rituximab in patients with CLL or SLL. The FDA has approved the new tablet formulation of acalabrutinib for CLL, SLL, and R/R MCL.
The European Commission has granted Marketing Authorization for the expanded use of ibrutinib. Ibrutinib combined with standard chemoimmunotherapy significantly prolonged progression-free survival in older patients. This article discusses managing the most difficult cases of CLL. The phase I/II study examined the use of the Bruton’s tyrosine kinase inhibitor in 385 patients. Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting. The study included adults with treatment-naïve and relapsed/refractory CLL or small lymphocytic leukemia. Updated findings from the ASCEND study were presented at the 2022 ASCO Annual Meeting.